潰瘍性大腸炎患者を対象としたブラジクマブの非盲検延長試験

基本情報

NCT ID

NCT04277546

ステータス

中止

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

57

治験依頼者名

AstraZeneca

概要

The purpose of this OLE Study D5272C00002 (Legacy #3151-202-008) is to permit participants who previously enrolled in the double-blind Study D5272C00001 (Legacy #3151-201-008) to receive brazikumab, allowing for long-term observation of safety and efficacy in these participants treated with brazikumab. There are no formal hypotheses to be tested. Safety and efficacy data obtained in this study will be included in regulatory product submissions as appropriate.

対象疾患

介入

依頼者（Sponsor）